section name header

Pronunciation

ess-TAZ-oh-lam

Classifications

Therapeutic Classification: sedative/hypnotics

Pharmacologic Classification: benzodiazepines

Indications

BEERS REMS


Action

  • Depresses the CNS, probably by potentiating GABA, an inhibitory neurotransmitter.
Therapeutic effects:
  • Relief of insomnia.

Pharmacokinetics

Absorption: Well absorbed following oral administration.

Distribution: Highly lipid-soluble. Crosses the blood-brain barrier.

Protein Binding: 93%.

Metabolism/Excretion: Mostly metabolized by the liver; metabolites do not have CNS depressant activity.

Half-Life: 10–24 hr.

Time/Action Profile

(hypnotic activity)

ROUTEONSETPEAKDURATION
PO15–30 min2 hr6–8 hr



Plasma level.



Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: chest pain

EENT: pharyngitis

GI: abdominal pain, dyspepsia, nausea

MS: back pain, lower extremity pain, stiffness

Neuro: drowsiness, headache, weakness, abnormal coordination, abnormal dreams, abnormal thinking, behavior changes, confusion, depression, dizziness, hallucinations, hypokinesia, hangover, malaise, nervousness, sleep-driving

Misc: ANAPHYLAXIS, physical dependence, psychological dependence

Interactions

Drug-drug:

Drug-Natural Products:

Route/Dosage

Availability

(Generic available)

Assessment

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Prosom

Contr. Subst. Schedule

Schedule IV (C-IV)